Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Santen, Arctic Vision to Launch ARVN001 in China
Clearside Biomedical has announced that Arctic Vision, its Asia-Pacific partner, has signed a commercial collaboration agreement with Santen Pharmaceutical Co. for ARVN001 (known in the United States as XIPERE) to treat uveitic macular edema (UME) and additional ophthalmic indications in…
FDA Clears HG202 CRISPR Therapy for Wet AMD Trials
The U.S. FDA has granted investigational drug clearance for HG202, a pioneering CRISPR/Cas13Y RNA-editing therapy developed by HuidaGene to treat neovascular (wet) age-related macular degeneration (AMD). This milestone makes HG202 the first CRISPR/Cas13Y RNA-targeting therapy in clinical development and the…
Tobramycin/Dexamethasone (TobraDex): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing – WebMD
Tobramycin/Dexamethasone (TobraDex): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing WebMD Source: Author: | Date: 2024-11-06 08:00:00 Source: Author: | Date: 2024-11-06 08:00:00
Erythromycin ophthalmic (Ilotycin, Romycin): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing – WebMD
Erythromycin ophthalmic (Ilotycin, Romycin): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing WebMD Source: Author: | Date: 2024-11-06 08:00:00 Source: Author: | Date: 2024-11-06 08:00:00
VSY Biotechnology Unveils Maestro® Sinusoidal IOL at ESCRS24
VSY Biotechnology to Complete Global Rollout of its Sinusoidal Vision Technology (SVT®) at ESCRS 2024 This year’s European Society of Cataract and Refractive Surgeons (ESCRS) 2024 kicked off with the highly anticipated third iNovation Day, which brought together the medical…
BlueRock Therapeutics’ OpCT-001 Receives FDA Clearance
BlueRock Therapeutics, a subsidiary of Bayer, announced that the FDA has cleared its investigational new drug (IND) application for OpCT-001, a stem cell therapy designed to treat primary photoreceptor diseases. The clearance allows BlueRock to initiate a phase 1/2a clinical…
ChatGPT-4o Shows Promise in Addressing Retinal Diseases
A recent study highlights the potential of ChatGPT-4o in accurately answering questions related to retinal diseases, covering diagnostic criteria, treatment guidelines, and management strategies. The AI’s performance was evaluated by vitreoretinal specialists, focusing on its alignment with the American Academy of…
Atsena Publishes 12-Month Data on ATSN-101 for LCA1
Atsena Therapeutics announced that 12-month safety and efficacy data from its Phase I/II trial of ATSN-101, a gene therapy for Leber congenital amaurosis caused by GUCY2D mutations (LCA1), were published in The Lancet. ATSN-101 showed durable improvements in vision at…
Midwestern University Clinics Add New Specialty Faculty in Ophthalmology, Family Medicine – Midwestern University
Midwestern University Clinics Add New Specialty Faculty in Ophthalmology, Family Medicine Midwestern University Source: Author: | Date: 2024-11-05 08:00:00 Source: Author: | Date: 2024-11-05 08:00:00
$6.4M Grant for New Dry AMD & Stargardt Treatments
Dr. Christopher Cioffi, the Thomas and Constance D’Ambra Professor in Organic Chemistry at Rensselaer Polytechnic Institute, is collaborating with Dr. Konstantin Petrukhin, Professor of Ophthalmic Science at Columbia University, to develop promising compounds aimed at treating dry age-related macular degeneration…